Curi Bio

Curi Bio accelerates the discovery of next-generation medicines by integrating human cells, systems, and data. They offer advanced 3D tissue models of disease, biosystems for clinically relevant functional analyses, and AI/ML-enabled insights. This platform merges functional and analytical assessments for drug safety, efficacy, and potency, providing novel workflows and critical human data to inform R&D decision-making.

3D tissueAI/MLBiosystemsCardiacContractilityDrug DiscoveryHuman DataSkeletal Musclecuribio.com

Curi Bio

3D tissueAI/MLBiosystemsCardiacContractilityDrug DiscoveryHuman DataSkeletal Musclecuribio.com

HQSeattle, US

Team Size61

Open Jobs1

Total Funding$30M

Latest Fundraise3 months ago

TL;DR

Founded: 2015 (originally NanoSurface Biomedical; rebranded to Curi Bio in July 2020)

Headquarters: Seattle, WA (additional offices listed in Boston and Amsterdam)

What they do: Develop iPSC-derived 3D tissue models, biosystems, and AI/ML analytics (The Curi Engine) to generate human-relevant functional data for preclinical drug discovery

Notable products: Mantarray, Nautilus, Stingray (engineered tissue/biosystem platforms)

Latest equity funding: Series B — $10M closed Dec 2, 2025 (led by DreamCIS)

Non-dilutive funding: Reported NIH SBIR awards totaling $4.4M (Aug 23, 2023); total NIH non-dilutive funding reported >$12M

Company Overview

Problem Domain

Preclinical drug discovery and development — generating human-relevant functional and phenotypic data for safety, efficacy, and potency assessment.

Founded

2015

Industry

Biotechnology Research

Tech Stack

iPSC-derived cell models

3D engineered tissue models

Biosystems platforms (Mantarray, Nautilus, Stingray)

AI/ML-enabled phenotypic and data analytics

Automated contractility and functional assays

Funding Track Record

Series A (initial close)- 2021-03-18

6000000 USD

Announced as a $6M Series A (expected additional investors by end of Q2 2021).

Series A (second/oversubscribed close)- 2021-12-29

10000000 USD

Described as a second closing of an oversubscribed Series A totaling $10M.

Grant (NIH SBIR)- 2023-08-23

4400000 USD

Two SBIR grants totaling $4.4M; company reported total NIH non-dilutive funding >$12M as of this date.

Series B- 2025-12-02

10000000 USD

Announced as a $10M Series B to scale platforms and advanced data analysis.

Investor Signal

“Backed by venture investors including Dynamk Capital, UTC Investment, DS Asset Management and DreamCIS; has received significant NIH SBIR/NIH non-dilutive support.”

Founders

What we do

TL;DR

Company Overview

Funding Track Record

Founders

What we do

Curi Bio

3D tissueAI/MLBiosystemsCardiacContractilityDrug DiscoveryHuman DataSkeletal Musclecuribio.com

Curi Bio

3D tissueAI/MLBiosystemsCardiacContractilityDrug DiscoveryHuman DataSkeletal Musclecuribio.com

HQSeattle, US

Team Size61

Open Jobs1

Total Funding$30M

Latest Fundraise3 months ago

TL;DR

Founded: 2015 (originally NanoSurface Biomedical; rebranded to Curi Bio in July 2020)

Headquarters: Seattle, WA (additional offices listed in Boston and Amsterdam)

What they do: Develop iPSC-derived 3D tissue models, biosystems, and AI/ML analytics (The Curi Engine) to generate human-relevant functional data for preclinical drug discovery

Notable products: Mantarray, Nautilus, Stingray (engineered tissue/biosystem platforms)

Latest equity funding: Series B — $10M closed Dec 2, 2025 (led by DreamCIS)

Non-dilutive funding: Reported NIH SBIR awards totaling $4.4M (Aug 23, 2023); total NIH non-dilutive funding reported >$12M

Related Companies

Company	HQ	Industry	Total Funding
Parallel Bio	🇺🇸Watertown, US	BiotechnologyDeepTechHealth	$26M
Triplebar	🇺🇸Emeryville, US	BiotechnologyDeepTech	$21M
Cellcraft	🇬🇧Cambridge, GB	Agriculture and FarmingBiotechnologyDeepTech	$5M
Character Biosciences	🇺🇸San Francisco, US	BiotechnologyDeepTech	$137M
Outpace Bio	🇺🇸Seattle, US	BiotechnologyDeepTech	$199M